Thermo Fisher Scientific (TMO) Q3 FY25 earnings call

Thermo Fisher Scientific delivered an outstanding Q3 FY25, driven by strong operational execution and the PPI Business System, leading to significant earnings growth and a raised full-year outlook. The company actively advanced its growth and capital deployment strategies, including strategic M&A and share repurchases, while navigating mixed end-market conditions and leveraging innovation and AI partnerships for future growth. Management expressed confidence in its midterm and long-term organic growth targets.